DARPA-Funded DNA Ebola Vaccine Trial Open for Enrollment
May 20, 2015
An academic-industrial consortium funded in part by the U.S. Defense Advanced Research Projects Agency (DARPA) is taking a multi-faceted approach to develop products to both prevent and treat Ebola infection. At the University of Pennsylvania, the DARPA-funded initiative is testing a DNA Ebola vaccine that was developed in the lab of Dr. David Weiner, professor of Pathology and Laboratory Medicine. The vaccine testing clinical trial is now open for enrollment at Penn. The phase I trial, under the direction of Dr. Pablo Tebas from the Clinical Trials Unit, will evaluate safety, tolerability and immune responses of this newly developed DNA-based Ebola immunotherapy. Other academic collaborators in the consortium include Emory, Vanderbilt, University of Miami, and the Public Health Agency of Canada (University of Winnipeg).